Short Communication Alpha-Interferon, Cortical Blindness

Cancer Chemotherapy and Pharmacology

, Volume 29, Issue 4, pp 329-330

First online:

Interferon-related cortical blindness

  • Ofer MerimskyAffiliated withDepartment of Oncology, Tel-Aviv Medical Center
  • , Puiu NisipeanuAffiliated withDepartment of Neurology, Tel-Aviv Medical Center
  • , Anat LoewensteinAffiliated withDepartment of Ophthalmology, Tel-Aviv Medical Center
  • , Irith Reider-GroswasserAffiliated withSection of Neuroradiology, Tel-Aviv Medical CenterFaculty of Medicine, Tel-Aviv University
  • , Samario ChaitchikAffiliated withDepartment of Oncology, Tel-Aviv Medical Center

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The term cortical blindness indicates loss of sight due to bilateral lesions in the occipital lobes. It is a rare but severe side effect produced by chemotherapeutic agents. Cortical blindness was diagnosed in a 75-year-old man who had been treated with alpha-interferon for metastatic renal-cell carcinoma. The absence of focal neurological signs and of abnormal findings as determined by two repeated computed tomography (CT) scans of the brain, which excluded structural damge to the occipital lobes, suggest that metabolic or toxic reactions may have caused the cortical blindness diagnosed in our patient. The temporal relationship between the treatment with alpha-interferon and the development of cortical blindness indicates that this substance may have been the causative agent for this phenomenon.